Oncology doctors are considering new ways in addition to conventional care to improve cancer outcomes. Examples of integrative medicine include acupuncture, mind-body approaches, and botanicals. Dr. Heather Greenlee of Columbia University Mailman School of Public Health will discuss new guidelines developed within the Society for Integrative Oncology.
Evidence-based guidelines for the nutritional management of adult oncology pa...milfamln
Webinar Objectives
1. The participant will be able to discuss the validity of malnutrition screening and nutrition assessment tools and their utilization in clinical oncology settings
2. The participant will be able to better utilize the Nutrition Care Process to provide appropriate and high-quality nutrition care to oncology patients
3. The participant will be able to describe the evidencebased relationships between nutritional status and morbidity and mortality outcomes in oncology
A national approach to improve the quality of Aftercare for survivors of TYA cancer - End of Treatment Summaries / Care Plans
Dr Helen Jenkinson, Consultant Paediatric Oncologist
on behalf of the NCSI steering group
Event held in London on Wednesday 9 October with the Teenage and Young Adult (TYA) Centre Champions and our Clinical Leads to share learning, good practice examples, the successes, challenges and barriers to implementing:
Treatment summaries
End of treatment care plans
Increased self-management for TYAs after cancer treatment
The output from the meeting will be to define what support NHS IQ can provide locally to assist TYA teams in order to make progress with their implementation plans.
Evidence-based guidelines for the nutritional management of adult oncology pa...milfamln
Webinar Objectives
1. The participant will be able to discuss the validity of malnutrition screening and nutrition assessment tools and their utilization in clinical oncology settings
2. The participant will be able to better utilize the Nutrition Care Process to provide appropriate and high-quality nutrition care to oncology patients
3. The participant will be able to describe the evidencebased relationships between nutritional status and morbidity and mortality outcomes in oncology
A national approach to improve the quality of Aftercare for survivors of TYA cancer - End of Treatment Summaries / Care Plans
Dr Helen Jenkinson, Consultant Paediatric Oncologist
on behalf of the NCSI steering group
Event held in London on Wednesday 9 October with the Teenage and Young Adult (TYA) Centre Champions and our Clinical Leads to share learning, good practice examples, the successes, challenges and barriers to implementing:
Treatment summaries
End of treatment care plans
Increased self-management for TYAs after cancer treatment
The output from the meeting will be to define what support NHS IQ can provide locally to assist TYA teams in order to make progress with their implementation plans.
Nutrition is very important yet neglected in field of oncology.
Majority of healthcare providers know and practice very little on this burning issue!
It is proven that nutrition impacts on overall survival, treatment outcome & recovery in oncology.
This presentation will give you brief information regarding importance and need of nutrition in Oncology.
Strategies for Long-term Management of Recurrent Ovarian Cancerbkling
A panel of doctors and patients will discuss decision-making in the recurrent setting of ovarian cancer, including how to understand and consider options like chemotherapy, surgery, and clinical trials. Panelists include Dr. Jason Wright and Dr. June Hou from Columbia University College of Physicians and Surgeons, survivor/research advocate Annie Ellis, and others living with recurrence.
Nutrition is very important yet neglected in field of oncology.
Majority of healthcare providers know and practice very little on this burning issue!
It is proven that nutrition impacts on overall survival, treatment outcome & recovery in oncology.
This presentation will give you brief information regarding importance and need of nutrition in Oncology.
Strategies for Long-term Management of Recurrent Ovarian Cancerbkling
A panel of doctors and patients will discuss decision-making in the recurrent setting of ovarian cancer, including how to understand and consider options like chemotherapy, surgery, and clinical trials. Panelists include Dr. Jason Wright and Dr. June Hou from Columbia University College of Physicians and Surgeons, survivor/research advocate Annie Ellis, and others living with recurrence.
SHARE Presentation: Write your own memoir with Abigail Thomasbkling
Best-selling author Abigail Thomas talks about memoir writing, her own creative process, and effective ways to start and complete a memoir. She is the author of A Three Dog Life and Safekeeping, among other books. She teaches writing workshops and leads the Memoir Group at Kingston 's Oncology Support Program of the HealthAlliance of the Hudson Valley. Listen to the recording here: http://bit.ly/MemoirI
SHARE Presentation: Write Your Own Memoir, Part II with Abigail Thomasbkling
Part II of a special two-part webinar series offering tips on writing your story. Abigail Thomas, author of A Three Dog Life and Safekeeping, among other books, is the presenter. Listen to the recording here: http://bit.ly/MemoirII
Legal Issues Raised by Genetic Testing: Genetic Discrimination and Gene Patentsbkling
ACLU Attorney Sandra Park presented at SHARE on the legal protections afforded to people who have a known genetic mutation, such as BRCA 1 or 2, or who are planning to get genetic testing. Some employers may discriminate, but under the Genetic Information Non-Discrimination Act, legal protections are in place. Learn about them.
The information in this video is not intended to be a substitute for professional medical advice, diagnosis or treatment. If you'd like to view the complete webinar, go to www.sharecancersupport.org/park
SHARE Webinar: Why Should I Join a Clinical Trial with Dr. Hershmanbkling
Dr. Dawn L. Hershman of the Herbert Irving Comprehensive Cancer Center at Columbia University presented the basics of clinical trials and emphasized how important it is for more patients to participate in them. She also discussed trials currently available for early stage and metastatic breast cancers. The webinar was presented on June 25, 2014. To hear the webinar, visit www.sharecancersupport.org/hershman
How We Do Harm: A Webinar by SHARE with Dr. Otis Brawleybkling
Dr. Otis Brawley, author of How We Do Harm, pulls back the curtain on how health care is really practiced in American. Hosted by SHARE: Self-help for Women with Breast or Ovarian Cancer.. www.sharecancersupport.org. If you would like to watch the full webinar, visit www.sharecancersupport.org/brawley.
SHARE Presentation: Coping With Cancer: If Cancer is a Gift, What's the Retur...bkling
Dr. Mindy Greenstein explores the balancing act of coping with cancer, based on personal and professional experience. Dr. Greenstein is a cancer psychologist and consultant to the psychiatry department at Memorial Sloan-Kettering Cancer Center, and a two-time breast cancer patient.
Integrative medicine - The link between red meat and cancerraynoronha
The media has recently reported the warnings from scientist regarding red meat consumption. This presentation uncovers the findings and provides guidelines for healthcare professionals and the public.
Communicating hope and truth: A presentation for health care professionalsbkling
Dr. Don S. Dizon, gynecologic oncologist at Massachusetts General Hospital Cancer Center, discusses the lessons he's learned while trying to communicate in an honest and hopeful way with patients facing a difficult diagnosis. This was presented as a webinar hosted by SHARE. If you'd like to view the complete webinar, go to www.sharecancersupport.org/dizon
Integrative medicine expert and media and marketing veteran Glenn Sabin explains why inbound content marketing and storytelling is the most pragmatic approach to building patient volume and sales for integrative healthcare clinics, centers and brands.
H. Kim Lyerly, M.D., FACS, discusses research in tumor dormancy in breast cancer, including the role of disseminated tumor cells, bone marrow, and the potential for immune responses to control or prevent recurrences. Dr. Lyerly is Director of the Center of Applied Therapeutics at Duke University.
Finding a Clinical Trial That's Right for Youbkling
Elly Cohen, PhD, Program Director of BreastCancerTrials.org, works closely with breast cancer organizations that promote patient awareness of clinical trials as a routine option for care. In this webinar, Elly walked listeners through the steps involved in finding clinical trials that are specific to their diagnosis.
Facing Forward: When Cancer Changes the Road Aheadbkling
A breast or ovarian cancer diagnosis brings unimaginable changes to a woman's life. Join us for a webinar as Julie Larson, LCSW, helps you reflect upon the psychological impact of this diagnosis. Learn how to develop strategies to face the challenges and emotions of your new normal.
Clinical Trials for Ovarian Cancer: Fact vs. Fictionbkling
Courtney Hudson, CEO & Co-Founder of EmergingMed, explains the basics of clinical trials and the process of developing new treatments in the emerging age of personalized medicine and immunotherapy. Lean how to identify appropriate clinical trials, find strategies to determine your best options, and figure out which questions to ask when making your decisions. Watch the accompanying webinar: https://vimeo.com/203510985
Dr. Stephanie Blank and Dr. Melissa Frey update us on the latest developments in ovarian cancer research and treatment from the annual conference of the Society of Gynecologic Oncology. Dr. Blank is a gynecologic oncologist at Perlmutter Cancer Center at NYU Langone Medical Center and an associate professor at NYU School of Medicine. Dr. Frey is a Gynecological Oncology Fellow at NYU Langone Medical Center.
SHARE Presentation: New Developments in the Medical Treatment of Breast Cance...bkling
Dr. Cliff Hudis on the latest information on new breast cancer treatments. Dr. Hudis is Chief of Breast Cancer Medicine Service at Memorial Sloan-Kettering Cancer Center.
Invasive Lobular Carcinoma — Highlights from the First Ever ILC Symposium bkling
Steffi Osterreich, PhD, and Rachel Jankowitz, MD, of University of Pittsburgh Cancer Institute, join Heather Hillier, breast advocate and co-chair of the first international ILC Symposium, in offering an overview of Invasive Lobular Carcinoma and highlights from the conference, which took place in Pittsburgh in September 2016. The program was presented in collaboration with MBCN.
Many complementary therapies, used along with conventional medicine, can support cancer treatments, reduce some of the adverse effects of cancer treatment, ease tension and pain, and contribute to overall health. This is known as integrative medicine. Integrative medicine can be a part of your plan throughout the entire treatment and survivorship experience. In this webinar, we will talk about how integration can be helpful to you after a colorectal cancer diagnosis and your journey forward.
Presented by Dr. Lisa Corbin: a board-certified internist, Associate Professor in the Department of Internal Medicine at the University of Colorado School of Medicine. In 2001, she helped the University of Colorado Hospital establish the Center for Integrative Medicine (TCFIM) and has served as the Medical Director ever since.
Cardiac rehabilitation is a comprehensive program that aims to improve the health and quality of life of individuals with cardiovascular disease. This article provides an overview of current evidence-based practices and the benefits of cardiac rehabilitation. The article discusses the components of cardiac rehabilitation, including medical evaluation, physical activity and exercise training, nutrition counseling and education, psychosocial support and counseling, cardiac risk factor management, medication management, and tobacco cessation counseling. The lecture also discusses the effectiveness of cardiac rehabilitation in reducing mortality rates, improving functional capacity, and reducing the risk of future cardiovascular events. Additionally, the article explores the future directions of cardiac rehabilitation, including personalized medicine, technology integration, home-based programs, expanded target populations, and a multidisciplinary approach. Healthcare providers play a crucial role in encouraging and referring eligible patients to cardiac rehabilitation programs as part of their treatment plan. It concludes that cardiac rehabilitation is an essential aspect of the management of cardiovascular disease and highlights the need for further research and development in this dynamic field.
Thinking About Success and Failure in Obesity CareObesityHelp
Even though obesity has officially been classified as disease by important groups like the American Medical Association, many people – doctors included – put all the emphasis on the scale and on other measures like body mass index (BMI). In this talk we will look at how success is measured now and other ways to define success after bariatric surgery. Time allowing, we will also talk about some of the long-term issues related to health and nutrition after bariatric surgery, with a focus on things that contribute to weight regain.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Let's Talk About It: Ovarian Cancer (The Emotional Toll of Treatment Decision...bkling
Making treatment decisions is stressful. The work of understanding complex medical information, crafting questions for your medical team, and trusting oneself is hard. We break down this intense time in ways that might feel more manageable and help you regain a sense of calm as you work hard to care for yourself at each turn in the road. Let’s talk about it.
Report Back from SGO: What’s the Latest in Ovarian Cancer?bkling
Are you curious about what’s new in ovarian cancer research or unsure what the findings mean? Join Dr. Elena Pereira, a gynecologic oncologist at Lenox Hill Hospital, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Pereira will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Part I - Anticipatory Grief: Experiencing grief before the loss has happenedbkling
Anticipatory grief is the emotional experience when there is an impending loss that will occur. Often, people associate loss and grief with death, this is just one area in which grief and loss can occur. Anticipatory grief is often a slower grieving process marked by intermittent, small or large losses. In the world of cancer, anticipatory grief may show up in a variety of ways, such as before a major surgery, losing hair from chemotherapy treatment or caring for a loved one with advanced cancer.
Learn about anticipatory grief and ways to cope with it. We will also explore methods to heal from this challenging experience.
See it and Catch it! Recognizing the Thought Traps that Negatively Impact How...bkling
A cancer diagnosis is stressful. Feelings of worry, fear, self-doubt, sadness, and loneliness are normal but can feel exhausting and consuming at times. Cultivating a habit of thought-watching and learning to recognize thought traps that might be contributing to our discomfort can help us respond and care for ourselves in helpful ways. Learn more about the connection between what we think and how we feel and what you can do about it that might impact how you feel today. Let’s talk about it.
Advocating for Better Outcomes: Ovarian Cancer and Youbkling
Many parts of your life can affect your health and your cancer risk. Things like your race, ethnicity, where you live, and your finances matter. Even so, how can you get the health care you need and lower your cancer risk? What should you and your family do if you need to speak up?
Join this special talk about knowing your risk, ovarian cancer care, and ways we can speak up to improve our health. provided by two experts from Memorial Sloan Kettering Cancer Center (MSK) and SHARE.
Do you want to feel empowered and confident in preserving your independence and lowering your risk for injury? Learn how to reduce the risk of injury, how to fall safely, and maximize quality of life. Avoid common pitfalls and connect with others who share this concern!
Speakers: Ayden Jones, Falls Prevention Consultant and A Matter of Balance Master Trainer, and Janvier Hoist-Forrester, OTS.
Embracing Life's Balancing Act: Part 2 - Fall Action Planbkling
Do you want to feel empowered and confident in preserving your independence and lowering your risk for injury? Learn how to reduce the risk of injury, how to fall safely, and maximize quality of life. Avoid common pitfalls and connect with others who share this concern!
Speakers: Ayden Jones, Falls Prevention Consultant and A Matter of Balance Master Trainer, and Janvier Hoist-Forrester, OTS.
Let's Talk About It: Communication, Intimacy, and Sex… Oh My!bkling
Changes to your body are normal to experience related to a cancer diagnosis. But the grief and the learning to live with a changed body take time. But what if you share your body with someone else? What if finding pleasure and connection through intimacy feels like an overwhelming or insurmountable obstacle on your road to healing? Let's talk together about our personal experiences and questions surrounding this important topic of communication and intimacy.
Let's Talk About It: To Disclose or Not to Disclose?bkling
Sharing your cancer diagnosis with others can bring up a range of unexpected feelings and questions. Deciding who you tell, how much to share, and why are all important things to consider. The answer to these questions is personal and it varies not only between survivors but also in different settings and relationships in your life. We talk together about personal experiences and questions surrounding this important topic.
Report Back from SGO: What’s New in Uterine Cancer?.pptxbkling
Dr. Ebony Hoskins, gynecologic oncologist at MedStar Washington Hospital Center, provides a comprehensive update from the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer. Dr. Hoskins breaks down the research presented at the conference, discusses new developments, and addresses the most pressing questions.
Learn Tips for Managing Chemobrain or Mental Fogginessbkling
Chemobrain, or mental fogginess, is experienced by many patients during and after cancer treatment. But what are some strategies that help?Dennis Lin, OTD, OTR/L, Occupational Therapist at City of Hope National Medical Center, will provide tips on how you can manage chemobrain and support better engagement in your daily life.
Vaccines: Will they become a form of Secondary and Primary Breast Cancer Prev...bkling
Our guest speaker Lee Gravatt Wilke, MD, Senior Medical Director at the University of Wisconsin School of Medicine and Public Health, explains the current state of vaccine clinical trials in breast cancer followed by a review of the STEMVAC trial, design of the vaccine, and the current state of the accrual and next steps.
Let's Talk About It: Uterine Cancer (Advance Care Planning)bkling
Although it can be a difficult topic, advance care planning is very important for anyone facing a cancer diagnosis. The goal of advance care planning is to set up a plan to make sure you get the care you want in the future. It is critical to prepare for future decisions about your medical care with your family and support system. We discuss how to start and continue those important conversations. Learn about the differences between palliative care and hospice, when to bring up your wishes with your medical team, and how to prepare your family for navigating these decisions.
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...bkling
You’ve been treated for uterine cancer. Now what? With surveillance strategies varying from doctor to doctor, it can be hard to know which advice you should follow. Dr. Jennifer Mueller, Head of the Endometrial Cancer Section, Gynecologic Oncology Service at Memorial Sloan Kettering Cancer Center, delves into surveillance guidelines, which tests to consider, and how to keep an eye out for any symptoms which could indicate recurrence.
Understanding and Managing Chemo-Induced Peripheral Neuropathy (CIPN)bkling
Certain chemotherapy drugs can cause chemotherapy-induced peripheral neuropathy (CIPN), which is one of the most common side effects of treatment. Chemotherapy treatments cause peripheral neuropathy by damaging the nerves in the fingers, hands, arms, legs, and feet. This can lead to symptoms including pain, numbness, tingling, and difficulty with mobility, which can greatly impact one’s quality of life. Dr. Anasheh Halabi is an Assistant Clinical Professor in Neuromuscular Medicine at UCLA who specializes in neuropathies and is a leading specialist in caring for patients with neurotoxicities related to cancer drugs. She discusses chemotherapy-related neuropathies, expectations, and management. The perspective of a patient who has experienced CIPN will also be included in the program.
Let's Talk About It: Sick and Tired of Being Sick and Tiredbkling
Cancer-related fatigue is one of the most challenging treatment-related side effects. Your level of cancer-related fatigue may vary from day to day or last for extended periods. Survivors experience fatigue related to cancer treatment, but fatigue can also be a side effect of the logistical, mental, and emotional toll cancer takes on someone. This mental and emotional fatigue can often be minimized and particularly challenging to cope with as a survivor. Learn how to address your fatigue in mindful ways so you can navigate the days ahead.
What’s New with PARP Inhibitors and Ovarian Cancer?bkling
PARP inhibitors have revolutionized ovarian cancer treatment, but recent updates to the FDA-approved indications have caused confusion and raised questions for patients. So what do these changes mean? Dr. Thomas Herzog, Deputy Director of the University of Cincinnati Cancer Center, discusses the current landscape of PARP inhibitors for ovarian cancer and what it means for you.
Caring for You: The Mental & Emotional Toll of Survivorshipbkling
A cancer diagnosis is stressful. From gathering information about treatment options to navigating relationships with loved ones, it is normal to feel overwhelmed and emotional. This session will provide concrete tools for sharpening self-awareness to better understand needs and gain strategies for coping with intense emotions like worry and fear.
Let's Talk About It: Ovarian Cancer (Shifting Focus: The Relationship with Yo...bkling
Cancer treatment can change the relationship you have with your body. Surgical scars, hair loss, changes in sensitivity, discomfort or pain, and ongoing side effects can be overwhelming and emotional to experience. Feelings of loss, disconnect, anger, and shame are normal to have but can be uncomfortable or complicated to navigate. Join us on Wednesday, February 14th as together we openly discuss the path forward to healing and reclaiming the important relationship with your body post-diagnosis.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
SHARE Presentation: Integrative Medicine and Cancer with Dr. Heather Greenlee
1. Integrative Medicine
and Cancer
SHARE
October 15, 2015
Heather Greenlee, ND, PhD, MPH
Assistant Professor of Epidemiology
Mailman School of Public Health
Herbert Irving Comprehensive Cancer Center
Columbia University
2. • The evidence-based use of complementary and
supportive therapies in conjunction with
conventional cancer therapies.
• Therapies include:
o Mind-body modalities
o Dietary supplements
o Food and nutrition
o Exercise and physical activity
o Acupuncture
o Massage
Integrative Oncology
3.
4. “Clinical Practice
Guidelines are
statements that include
recommendations
intended to optimize
patient care that are
informed by a systematic
review of evidence and
an assessment of the
benefits and harms of
alternative care options.”
– 2011, US Institute of Medicine
8. Complementary & integrative medicine (CIM)
use among breast cancer survivors
• 2.8+ million breast cancer survivors in the US
• 48-80% of breast cancer patients use CIM
• Intended uses of CIM after diagnosis include:
– Prevent & treat side effects of conventional therapies
– Improve quality of life, functional status and emotional state
– Increase efficacy of conventional cancer therapies
– Secondary cancer prevention
– Meet needs not addressed by conventional therapies
– Treat comorbidities
– Health promotion
10. Guidelines Working Group
Co-Chairs
• Heather Greenlee, ND, PhD, MPH – naturopathic medicine, acupuncture, natural
products, epidemiology, clinical trials
• Debu Tripathy, MD – breast medical oncology, natural products, clinical trials
Members
• Lynda Balneaves, PhD, RN – nursing, natural products, clinical trials
• Linda Carlson, PhD, Rpsych – clinical psychology, mind-body, clinical trials
• Misha Cohen, OMD, LAc – acupuncture, Chinese herbal medicine, clinical trials
• Gary Deng, MD, PhD – integrative med, acupuncture, Chinese med, clinical trials
• Dawn Hershman, MD, MS – breast medical oncology, natural products,
epidemiology, clinical trials
• Matthew Mumber, MD – radiation oncology, mind-body interventions
• Jane Perlmutter – patient advocacy
• Dugald Seely, ND, MS – naturopathic med, research methods, systematic
reviews, clinical trials
• Ananda Sen, PhD - biostatistics
• Suzanna Zick, ND, MPH – naturopathic med, natural products, acupressure,
epidemiology, clinical trials
11. Inclusion criteria
1. Randomized controlled trial published Jan 1990 – Dec 2013
2. Available in English
3. Included ≥50% breast cancer patients and/or reported
results separately for breast cancer patients
4. Used an integrative modality as an intervention during
standard treatment with surgery, chemotherapy, radiation
therapy, and/or hormonal therapy, or addressed long-term
side effects resulting from diagnosis and/or treatment
5. Assessed a clinical outcome of interest
Other systematic reviews and meta-analyses were excluded.
12. Search results
• 4,900 unique articles
• Article titles and abstracts were initially screened
by at least 2 reviewers for inclusion for full review
• Full-text of articles that met criteria were
assembled in online database accessible to the
working group (Mendeley)
• Second round of screening consisted of a full-text
scan to further remove articles that did not meet
the inclusion criteria
• 203 articles met the criteria for final inclusion
13.
14. USPSTF grades
Grade Definition Suggestions for Practice
A Recommends the modality. There is high
certainty that the net benefit is substantial.
Offer/provide this modality.
B Recommends the modality. There is high
certainty that the net benefit is moderate or
there is moderate certainty that the net
benefit is moderate to substantial.
Offer/provide this modality.
C Recommends selectively offering or
providing this service to individual patients
based on professional judgment and
patient preferences. There is at least
moderate certainty that the net benefit is
small.
Offer/provide this modality for
selected patients depending on
individual circumstances.
D Recommends against the service. There is
moderate or high certainty that the
modality has no net benefit.
Discourage the use of this
modality.
H Recommends against the service. There is
moderate or high certainty that the harms
outweigh the benefits.
Discourage the use of this
modality.
I statement Concludes that the current evidence is
insufficient to assess the balance of
benefits and harms of the service.
Evidence is lacking, of poor quality, or
conflicting, and the balance of benefits and
harms cannot be determined.
Read the Clinical Considerations
section of the USPSTF
Recommendation Statement. If the
service is offered, patients should
understand the uncertainty about
the balance of benefits and harms.
*Adapted from U.S. Preventive Services Task Force
http://www.uspreventiveservicestaskforce.org/uspstf/grades.htm.
15. Anxiety / stress reduction
Grade B
Grade B
• Music therapy is recommended for reducing anxiety during radiation therapy
(RT) and chemotherapy (CT) sessions.
• Meditation is recommended for reducing anxiety in BC patients and those
undergoing RT.
• Stress management is recommended for reducing anxiety during treatment,
but longer group programs are likely better than self-administered home
programs or shorter programs.
• Yoga is recommended for reducing anxiety in BC patients undergoing RT +/-
CT and suggested for fatigued patients.
16. Anxiety / stress reduction
Grade C
Grade C
• Acupuncture can be considered for reducing anxiety in fatigued BC patients.
• Massage can be considered for short-term reduction of anxiety in BC patients.
• Relaxation can be considered for treating anxiety during treatment.
17. Depression / mood
Grades A & B
Grade A
• Meditation, particularly MBSR, is
recommended for treating mood
disturbance and depressive symptoms in
BC patients undergoing RT.
• Relaxation is recommended for improving
mood and depressive symptoms when
added to SC.
• Yoga is recommended for improving mood
in women undergoing RT +/- CT and for
fatigued BC patients in addition to SC.
Grade B
• Massage is recommended for improving
mood disturbance in post-treatment BC
patients.
• Music therapy is recommended for
improving mood in newly diagnosed BC
patients.
18. Depression / mood
Grade C
Grade C
• Acupuncture can be considered for improving
mood in postmenopausal women experiencing
hot flashes or fatigue.
• Healing touch can be considered for improving
mood in BC patients undergoing CT.
• Stress management interventions with or
without exercise can be considered for
improving mood in BC patients.
19. Fatigue
Grades B & C
Grade B
• Energy conservation counseling is
recommended for the treatment of fatigue.
Grade C
• American Ginseng is recommended as an
herbal approach for the treatment of fatigue in
BC patients.
• Acupuncture can be considered for the
treatment of fatigue after the completion of
cancer treatments.
• Modified qigong can be considered for the
treatment of fatigue in BC patients.
20. Fatigue
Grade D
Grade D
• Acetyl-L-carnitine is not recommended for the treatment of fatigue due to
lack of effect.
• Guarana is not recommended as an herbal for the treatment of fatigue due to
lack of effect.
XX
21. Sleep
Grade C
Grade C
• Stress management techniques can be considered for the treatment of sleep
disruption.
• Gentle yoga can be considered for the treatment of sleep disruption.
22. Quality of life & physical functioning
Grade A
Grade A
• Meditation is recommended for improving quality of life among BC patients.
23. Quality of life & physical functioning
Grade C
Grade C
• Acupuncture can be considered for improving quality of life among cancer
patients.
• Guided imagery can be considered for improving quality of life among BC
patients.
• Mistletoe can be considered for improving quality of life among BC patients.
• Qigong can be considered for improving quality of life in cancer patients.
• Reflexology can be considered for improving quality of life among BC patients.
• Stress management can be considered for improving quality of life among BC
patients.
• Yoga can be considered for improving quality of life among BC patients.
• Exercise awareness can be considered for improving functioning among BC
patients.
24. Chemotherapy induced nausea and
vomiting (CINV)
Grade B
Grade B
• Acupressure can be considered for BC patients receiving CT as an addition
to antiemetics to help control nausea and vomiting during CT.
• Electroacupuncture can be considered for BC patients as an addition to
antiemetics to control vomiting during CT.
25. Chemotherapy induced nausea and vomiting (CINV)
Grades C & D
Grade C
• Ginger can be considered for BC patients receiving CT, without concurrent RT
as an addition to antiemetics for the control of acute nausea.
• Progressive muscle relaxation can be considered for BC patients receiving
CT as an addition to antiemetics to help control nausea and vomiting during
CT.
Grade D
• Glutamine is not recommended for use by BC patients receiving CT for the
treatment of CINV due to lack of effect
X
26. Pain
Grade C
Grade C
• Energy and sleep enhancement can be
considered for pain associated with CT among
unemployed individuals.
• Massage and healing touch can be
considered for pain associated with CT.
• Music therapy can be considered to relieve
pain associated with surgery.
• A physical training program that includes a
mind-body modality can be considered for
relieving pain associated with surgery among
BC patients.
• Hypnosis can be considered for relief of
associated with surgery in BC patients.
• Acupuncture can be considered as a non-
pharmacologic approach to the short-term
treatment of aromatase inhibitor-associated
musculoskeletal symptoms (AIMSS).
• Electroacupuncture can be considered as a
non-pharmacologic approach to the short-term
treatment of AIMSS.
27. Neuropathy
Grades H & I
Grade H
• Acetyl-L-carnitine is not
recommended for
prevention of neuropathy in
BC patients due to harm.
Insufficient evidence
• Electroacupuncture, vitamin
B, omega-3 fatty acid,
vitamin E
X
28. Lymphedema
Grade C
Grade C
• Laser therapy can be considered as a treatment for lymphedema in BC
patients.
• Manual lymphatic drainage (MLD) and compression bandaging have been
shown to be equivalent. MLD can be considered for treatment of lymphedema
in BC patients who have sensitivity to bandaging.
29. Hot flashes
Grades C & D
Grade C
• Acupuncture can be considered for decreasing the number of hot flashes in
BC patients.
• Electroacupuncture can be considered for decreasing the number of hot
flashes in BC patients.
Grade D
• Soy is not recommended for the treatment of hot flashes in BC patients and
patients due to lack of effect.
X
30. Acute radiation skin reaction
Grade D
Grade D
• Aloe vera is not recommended as a standard therapy to prevent or treat acute
radiation skin reaction due to lack of effect.
• Hyaluronic acid cream is not recommended as a standard therapy to prevent
or treat acute radiation skin reaction due to lack of effect.
X X
31. Strengths, Limitations and Caveats
• Up to date summary of RCTs with defined grading system
• Excluded older literature, meta-analyses and reviews
• Excluded trials that had a minority of breast cancer patients
• May have missed some trials using different keywords, not
associated with cancer therapy
• Not all modalities (e.g., spirituality) were included
• Future trials need to standardize therapies, defined
symptoms/eligibility, outcome measures, toxicity
assessments
• Use of guidelines requires judgment, shared decision-
making, risk/benefit analysis depending on situation (e.g.,
curability), follow-up/surveillance and adjustments
32. Dissemination plan
• Published in Journal of the National Cancer
Institute Monograph – open access
• Press releases to media outlets
• Submit to national guidelines repositories
• Develop patient and provider friendly materials
• Advocate for high quality integrative oncology
research
• Post slidedeck on SIO website
33. Conclusions
• Clinical practice guidelines provide an aid to
making complex clinical decisions
• Improve the ability for patients and clinicians to
make healthcare decisions
• A body of evidence supports the routine use of
selected integrative modalities in the oncology
setting
• SIO aims to be the leader in developing
trustworthy guidelines focused on integrative
oncology
34. Many thanks
Research Assistants
Columbia University
Chip Bowman
Melissa Dupont-Reyes
Lindsay Greenawalt
Jennifer Mongiovi
Misa Nuccio
Wendy Yu
Canadian College of Naturopathic Medicine
Heidi Fritz
Amita Sachdev
Cheryl Karthaus
Ottawa Integrative Canter Center
Laura Weeks
University of British Columbia
Erin Waters
University of California, San Francisco
Caylie See
University of Calgary
Jillian Johnson
Rie Tamagawa
Jennifer White
University of Michigan
Kevin Shrestha
Tofa Khabir
Internal reviewers
SIO Board of Trustees
Donald Abrams
Lorenzo Cohen
Gustav J. Dobos
Erika Erickson
Omer Kucuk
Jun Mao
Gregory Plotnikoff
External reviewers
Gabriel N. Hortobagyi
Anna Wu
Musa Mayer
Eun-Sil Shelley Hwang
SIO Executive Committee
JNCI
Meredith Abel
Jan Martin
35.
36.
37. Mi Vida Saludable: Healthy Diet and Physical Activity for
Latina Breast Cancer Survivors
• The purpose of this study is to help Latina
breast cancer survivors make healthy diet
and physical activity changes
• The study involves taking part in four
4-hour Saturday morning sessions at
Teachers College Columbia University
• The sessions include nutrition and
physical activity education and cooking
classes
• Participants will receive a Fitbit
Eligibility Criteria
– Latina/Hispanic
– Breast cancer survivor
– Have access to a computer, iPad,
tablet or smartphone
– Have access to a phone with texting
abilities
– If yes, you may be eligible to
participate
If you would like to learn more about
this study, please contact:
Amanda Marín-Chollom
(212) 305-3640
am4508@cumc.columbia.edu